Sorafenib and sunitinib for elderly patients with renal cell carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sorafenib and sunitinib for elderly patients with renal cell carcinoma

Published:2013-07 Issue:3 Volume:4 Page:255-261
ISSN:1879-4068
Container-title:Journal of Geriatric Oncology
language:en
Short-container-title:Journal of Geriatric Oncology

Author:

Derbel Miled Olfa,Dionne Christine,Terret Catherine,Segura-Ferlay Céline,Flechon Aude,Neidhart Eve-Marie,Negrier Sylvie,Droz Jean-Pierre

Publisher

Elsevier BV

Subject

Geriatrics and Gerontology,Oncology

Reference15 articles.

1. The epidemiology of bladder and kidney cancer;Scelo;Clin Pract Urol,2007

2. Sorafenib in advanced clear-cell renal-cell carcinoma;Escudier;N Engl J Med,2007

3. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma;Motzer;J Clin Oncol,2009

4. for the AVOREN Trial Investigators. Bevacizumab plus interferon alfa-2a for the treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial;Escudier;Lancet,2007

5. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial;Motzer;Lancet,2008

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: A systematic review and meta-analysis;Medicine;2023-09-08

2. Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis;Frontiers in Oncology;2019-06-21

3. Assessing Outcomes and Prognostic Factors for First-Line Therapy in Elderly Patients With Metastatic Renal Cell Carcinoma: Real-Life Data From a Single United Kingdom Institution;Clinical Genitourinary Cancer;2019-06

4. Efficacy and safety of axitinib in elderly patients with metastatic renal cell carcinoma;Medical Oncology;2016-07-21

5. Inhibiteurs de tyrosine kinase ciblant l’angiogenèse et sujets âgés : tolérance, évaluation pré-thérapeutique et gestion des effets indésirables;Bulletin du Cancer;2016-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3